



## SciTech Development, LLC


### **SciTech Awarded \$250K Translational Research Grant from the NFCR**

(GROSSE POINTE FARMS, MI) August 13, 2019 – [SciTech Development](#), a clinical stage drug development company, is pleased to announce that it has recently been awarded a Translational Research Grant of \$250,000 from the National Foundation for Cancer Research (NFCR).

SciTech intends to use the grant for the scale-up, preparation and initiation of a Phase 1 clinical trial of ST-001 for the treatment of T-cell non-Hodgkin's lymphoma (NHL). SciTech is currently seeking a Series A equity raise of approximately \$15MM to bring its lead product ST-001 to market for the treatment of NHL and small cell lung cancer (SCLC).

SciTech's lead compound, ST-001 [nanoFenretinide](#), is a small-molecule cancer drug employing a nanoparticle suspension for intravenous administration. ST-001 is comprised of [fenretinide](#) in a patented combination with carefully selected non-toxic phospholipids. SciTech's product pipeline includes treatment for several other cancer indications.

The company has submitted an Investigational New Drug (IND) Application for ST-001 in the treatment of NHL. The FDA has already granted Orphan Drug Status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Information regarding SciTech's nano formulation technology and oncology drug product ST-001 is available from SciTech Development, LLC by calling (313) 938-5517 or online at <https://www.scitechdevelopment.com/> and  .

### **About SciTech Development**

SciTech Development, LLC is a clinical stage oncology drug company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland.

### **[Selected Product Pipeline](#)**

ST-001 – Intravenous fenretinide formulation for the treatment of NHL.

- ST-002 – Topical formulation for the treatment of various skin cancers and bed sores.
- ST-003 – Intravenous formulation for the treatment of small cell lung cancer (SCLC).
- ST-004 – Intravenous formulation for the treatment of metastatic breast cancer (MBC).
- ST-005 – Intravenous formulation for the treatment of neuroblastoma (pediatric cancer).
- ST-006 – Intravenous formulation for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).

## **About the National Foundation for Cancer Research (NFCR)**

The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization that provides scientists in the lab the funding they need to make game-changing discoveries in cancer treatments, detection, prevention and ultimately, a cure. NFCR has distinguished itself in the cancer research sector by emphasizing long-term, transformative research often overlooked by other major funding sources. With the help of more than 5.2 million individual donors over the last 45 years, NFCR has delivered more than \$373 million in funding to public education and cancer research leading to several important, life-saving discoveries. More information regarding the NFCR can be found online at <https://www.nfcr.org/>

**For More Information About SciTech:** Earle T. Holsapple, President  
SciTech Development, LLC  
(313) 938-5517

## **Forward-Looking Information**

This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. In particular, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.



###